Recent Updates
Recently added Catalysts

Bronchial basal cells

Phase 1

Chronic Obstructive Pulmonary Disease | Monoclonal antibody | Respiratory |cbdMD, Inc.|Last Updated: Mar 24, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

NO_TREATMENT_CONTROLLED
Total Trials1
Total Enrollment24

FDA Designations

No designations recorded

Clinical trial landscape

Bronchial basal cells · 1 trial · 1 indication

Phase 1 1
NCT03188627Autologous Bronchial Basal Cell Transplantation for Treatment of COPDChronic Obstructive Pulmonary Disease
COMPLETED24 Analytics
PHASE1COMPLETED
Autologous Bronchial Basal Cell Transplantation for Treatment of COPD
Chronic Obstructive Pulmonary DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Indicators for safety
1-6 months

Measured by blood routine test, urine routine test and blood chemistry panels

Diffusion capacity of CO (DLCO)
1-6 months

One of the indicators in pulmonary function test, the extent to which oxygen passes from the air sacs of the lungs into the blood

Secondary Endpoints

The ratio of forced expiratory volume in the first one second to the forced vital capacity (FEV1/FVC)
1-6 months
Maximum mid-expiratory flow (MMF)
1-6 months
Maximum voluntary ventilation (MVV)
1-6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Bronchial basal cellsEXPERIMENTALTransplantation of autologous bronchial basal cells
ControlNO_INTERVENTIONConventional treatment

Interventions

NameTypeDescription
Bronchial basal cellsBIOLOGICALTransplantation of autologous bronchial basal cells
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Aged between 40 to 75; * Diagnosed with COPD according the guideline (a. with symptoms of productive cough, sputum production or shortness of breath; b. with poor airflow as indicated by FEV1\<70% predicted value and FEV1/FVC \< 0.7 in pulmonary function test; c. with exclusio...

Countries:China
Unlock Eligibility Criteria

Frequently asked questions about Bronchial basal cells

What is Bronchial basal cells used for in Chronic Obstructive Pulmonary Disease?

Bronchial basal cells are an investigational cell therapy being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The therapy involves transplanting autologous bronchial basal cells, which are the patient's own cells, with the goal of repairing or regenerating damaged airway tissue. It is currently in Phase 1 clinical development.

Who is developing Bronchial basal cells?

Bronchial basal cells are being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The therapy is in Phase 1 clinical development for Chronic Obstructive Pulmonary Disease.

What phase is Bronchial basal cells in?

Bronchial basal cells are in Phase 1 clinical development. The therapy is investigational and has not been approved by regulatory authorities. A Phase 1 clinical trial for the treatment of Chronic Obstructive Pulmonary Disease has been completed.

What clinical trials is Bronchial basal cells in?

Bronchial basal cells have been studied in one completed Phase 1 clinical trial, identified as NCT03188627, titled 'Autologous Bronchial Basal Cell Transplantation for Treatment of COPD'. The trial enrolled 24 participants with Chronic Obstructive Pulmonary Disease in China and was not randomized or double-blinded.

Is Bronchial basal cells the same as autologous bronchial basal cell transplantation?

Bronchial basal cells refer to the cell therapy used in autologous bronchial basal cell transplantation, a procedure where a patient's own bronchial basal cells are collected and transplanted back to treat Chronic Obstructive Pulmonary Disease. The clinical trial NCT03188627 evaluated this approach in 24 participants.